KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Non-Current Debt (2022 - 2025)

Biogen has reported Non-Current Debt over the past 9 years, most recently at $6.3 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 38.26% year-over-year to $6.3 billion; the TTM value through Dec 2025 reached $6.3 billion, up 38.26%, while the annual FY2025 figure was $6.3 billion, 38.26% up from the prior year.
  • Non-Current Debt for Q4 2025 was $6.3 billion at Biogen, up from $4.5 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $6.8 billion in Q4 2023 and troughed at $4.5 billion in Q4 2024.
  • A 4-year average of $6.0 billion and a median of $6.3 billion in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: tumbled 33.01% in 2024 and later surged 38.26% in 2025.
  • Year by year, Non-Current Debt stood at $6.3 billion in 2022, then rose by 8.08% to $6.8 billion in 2023, then tumbled by 33.01% to $4.5 billion in 2024, then surged by 38.26% to $6.3 billion in 2025.
  • Business Quant data shows Non-Current Debt for BIIB at $6.3 billion in Q4 2025, $4.5 billion in Q4 2024, and $6.8 billion in Q4 2023.